Table 3.
Remission vs active disease in Juvenile Spondyloarthritis cohorts.
| Years recruited | Country | Y f/u | SpA #(%) of total cohort | % Active | % Remission (total) | % Remission (on med) | % Remission (off med) | % Continuous active | % Remit for 1y then flare | % TNFi | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1980–1985 | Norway | 15.3 | 55(33) ERA | 56 | 44 | – | – | – | – | 0 | (2) |
| 1980–1985 | Norway | 30 | 27(15) ERA 21(12) PsA 11(6) UA |
– | – | – | 37 48 64 |
– | – | 0 | (67) |
| 1970–1998 | Italy | 10 | 67 (10) SpA (ILAR/ESSG) | 64 | 36 | – | – | 52 | 15 | – | (68) |
| 1997–2000 | Nordic | 7 | 49(11) ERA 14(3.2) PsA 66(15) UA |
61 54 53 |
39 46 47 |
8 23 6 |
31 23 41 |
31 27 40 |
– | 17.5 for all JIA | (20) |
| 2002–2003 | Germany | 4 | 118 SpA (mNY or ESSG) | 54a | – | 43a | 23a | – | 14 | 6 | (17) |
| 1995–2010 | Taiwan | >1.5 | 73(37) ERA 3(1.5) PsA 5(2.6)UA |
56 0 20 |
44 100 80 |
11 33 0 |
33 67 80 |
48 0 0 |
8 0 20 |
12.8 for all JIA | (25) |
| 2005–2010 | Canada | 5 | 157(14) ERA 64(6) PsA 110(10) UA |
53 53 54 |
47 47 46 |
– | – | – | – | <20 | (69) |
| 2005–2010 | Canada (2 of above centers) | 5.6 | 52(21) ERA 10(4) PsA 13(5) US |
35 20 15 |
65 80 69 |
13 30 15 |
52 50 54 |
– | – | 22 for all JIA | (70) |
| 2013–2014 | Germany | 1 | 74(11) ERA 28(4) PsA 50(7) UA |
72 73 58 |
28b
29 42 |
– | – | – | – | 25 32 36 |
(71) |
| 2008–2015 | France | 2.6 | 114 ERA or ASAS | 45 | 55 | 35 | 20 | – | – | 42 | (16) |
| 1993–2018 | Taiwan | 7.7 |
73(40) ERA 1(0.5) PsA 1(0.5) UA |
66 | 34 | 7 | 27 | – | – | 78 | (27) |
Cohorts are listed by years of patient recruitment and cohort nationality (left columns).
Cohort acronyms: GESPIC, German Spondyloarthritis Inception Cohort; ReACCh-Out, Research in Arthritis in Canadian Children Emphasizing Outcomes); ICON, Inception Cohort of Newly Diagnosed Children with JIA; JCA, juvenile chronic arthritis; JRA, juvenile rheumatoid arthritis; JIA, juvenile idiopathic arthritis; ERA, enthesitis related arthritis; PsA, psoriatic arthritis; UA, undifferentiated arthritis; ESSG, European Spondyloarthropathy Study Group; mNY, modified New York criteria for ankylosing spondylitis; ILAR, International League against Rheumatism; ERA, enthesitis related arthritis; PsA, psoriatic arthritis; UA, undifferentiated arthritis; ASAS, Assessment of Spondyloarthritis International Society. Follow up years refers to mean or median, depending upon the study. Cohort specific details are in footnotes. TNFi: TNF inhibitor usage by end of study.
54% in active disease after 4y. 43% in remission on meds and 23% in remission off meds at 4y or within past 6 months.
Status of active or inactive disease during months 9–12. In ERA, 55% eventually attained disease remission, but at a mean of ~16 months.